Zhang et al. manufactured a live drug carrier, paclitaxel-in-liposomes-in-bacteria, which showed a quicker drug delivery and therefore, a remarkable inhibition of lung cell proliferation, amongst the downregulation of VEGF, showing a promising new therapy for lung cancer management [104]. Here, VEGFA is linked to lung cancer.